Breaking News Instant updates and real-time market news.

NLNK

NewLink Genetics

$7.32

(0.00%)

, INCY

Incyte

$83.07

-0.91 (-1.08%)

15:04
04/06/18
04/06
15:04
04/06/18
15:04

NewLink announces review of clinical programs after Incyte/Merck trial news

NewLink Genetics (NLNK) announced a review of its clinical programs. NewLink stated: "This morning's announcement by Incyte and Merck on the ECHO-301 trial for patients with advanced melanoma is a disappointing result for the IDO field. Indoximod, NewLink Genetics' IDO pathway inhibitor, has a differentiated mechanism of action which may demonstrate clinical benefit for patients where direct enzymatic inhibitors have not. In light of Incyte's announcement, however, NewLink is undertaking a review of its clinical programs and will provide an update when it is completed. NewLink Genetics has generated data for indoximod across several indications, and in combination with different modalities, suggesting the potential for indoximod to improve the outcomes for patients with cancer. The Company will present additional data at AACR next week, including a poster presentation further supporting indoximod's differentiated MOA and a plenary session presenting encouraging early clinical data of indoximod plus radiation for pediatric patients with diffuse intrinsic pontine glioma, a rare and lethal form of brain cancer."

NLNK

NewLink Genetics

$7.32

(0.00%)

INCY

Incyte

$83.07

-0.91 (-1.08%)

MRK

Merck

$53.05

-1.479 (-2.71%)

  • 06

    Apr

  • 09

    Apr

  • 14

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 01

    May

  • 12

    Jun

  • 23

    Oct

NLNK NewLink Genetics
$7.32

(0.00%)

01/08/18
STFL
01/08/18
NO CHANGE
STFL
Buy
NewLink Genetics timelines mostly in-line with prior guidance, says Stifel
Stifel analyst Stephen Willey noted that NewLink Genetics (NLNK) now expects to complete the majority of enrollment in the Indigo301 melanoma trial by year-end, versus its previous expectation to complete enrollment in 2018, which he said is likely due to additional time required for dose optimization of the novel indoximod salt formulation. The remainder of the 2018 calendar the company laid out is full of mostly expected catalysts and in-line with prior guidance, said Willey, who still expects NewLink to remain levered to Incyte's (INCY) date from the Phase 3 ECHO-301 trial. Willey keeps a Buy rating on NewLink shares.
03/02/18
STFL
03/02/18
NO CHANGE
Target $21
STFL
Buy
NewLink Genetics price target lowered to $21 from $25 at Stifel
Stifel analyst Stephen Willey said NewLink Genetics' approximately 2-month delay in starting patient enrollment into the randomized portion of the Phase 3 Indigo301 trial is an incremental negative, but noted that management remains confident in its ability to implement the "fundamentally-simple changes" needed and the delay may actually provide increased flexibility in terms of strategically pivoting off Phase 3 ECHO-301 data. He has "conservatively" pushed-out indoximod launch timelines and lowered his price target on NewLink shares to $21 from $25, but maintains a Buy rating on the stock.
04/06/18
CANT
04/06/18
NO CHANGE
Target $26
CANT
Overweight
Cantor says premature to assume NewLink trial will fail like Incyte's
NewLink Genetics' (NLNK) indoximod, which acts as a tryptophan mimetic rather than an IDO enzymatic inhibitor, has shown differentiated data versus Incyte's (INCY) epacadostat, Cantor Fitzgerald analyst Mara Goldstein tells investors in a research note. NewLink is trading down 37.5%, or $2.75, to $4.57 after Incyte announced that its ECHO-301 study of epacadostat plus Merck's (MRK) Keytruda versus Keytruda alone was unsuccessful in treating advanced melanoma. Goldstein thinks assuming failure of indoximod "may be premature," but she acknowledges that NewLink shares are likely to be pressured with the company's Phase III trial end likely over a year away. If indoximod is truly differentiated, however, NewLink shares will be higher than $26 given the "now likely limited competition," Goldstein contends. She reiterates an Overweight rating on the shares with a $26 price target.
04/06/18
RHCO
04/06/18
DOWNGRADE
RHCO
Hold
NewLink Genetics downgraded to Hold from Buy at SunTrust
INCY Incyte
$83.07

-0.91 (-1.08%)

04/06/18
GUGG
04/06/18
DOWNGRADE
GUGG
Neutral
Incyte downgraded to Neutral from Buy at Guggenheim
04/06/18
04/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Incyte (INCY) downgraded to Neutral from Buy at Guggenheim and to Market Perform from Outperform at William Blair. 2. Ormat Technologies (ORA) downgraded to Perform from Outperform at Oppenheimer with analyst Noah Kaye citing valuation. 3. Sprague Resources (SRLP) downgraded to Underweight from Neutral at JPMorgan with analyst Andrew Burd citing the stock's year-to-date outperformance for the downgrade. 4. Banc of California (BANC) downgraded to Underperform from Neutral at BofA/Merrill with analyst Ebrahim Poonwala saying the company's new management team is working towards achieving its long-term strategic targets but is cautious on elevated execution risk given the balance sheet overhaul and lower quality deposit base. 5. Xilinx (XLNX) downgraded to Underweight from Neutral at JPMorgan with analyst Harlan Sur saying he believes multiple compression is likely with basestation deployment in China likely to decline in 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/06/18
MZHO
04/06/18
NO CHANGE
Target $103
MZHO
Buy
Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover
Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.
MRK Merck
$53.05

-1.479 (-2.71%)

04/05/18
04/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Overweight from Equal Weight at Barclays with analyst Geoffrey Meacham saying he believes the company will continue to take share in first-line lung cancer, driven by positive KN-189 and KN-042 data. 2. Acuity Brands (AYI) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha saying he believes the stock is finally trading at a "reasonable valuation based on reasonable expectations." 3. AMD (AMD) upgraded to Buy from Hold at Stifel with analyst Kevin Cassidy citing valuation and the company's margin expansion potential. 4. Tiffany (TIF) upgraded to Buy from Hold at Loop Capital with analyst Laura Champine saying her initial meeting with the company's new CEO Alessandro Bogliogo added to her confidence. 5. Citi (C) and Wells Fargo (WFC) were upgraded to Buy from Neutral at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/06/18
WBLR
04/06/18
DOWNGRADE
WBLR
Market Perform
William Blair downgrades Incyte after metastatic melanoma study failure
William Blair analyst Katherine Xu downgraded Incyte (INCY) to Market Perform from Outperform after the company and partner Merck (MRK) announced that ECHO-301 did not meet one of the primary endpoints of improving progression-free survival and that overall survival, the other co-primary endpoint, was not expected to be met either. After taking epacadostat out of her model, the analyst's fair value estimate for Incyte drops to $88 from $170. The stock in premarket trading is down 21%, or $17.08, to $65.99. It is unclear whether the biomarker data derived from ECHO-301 could guide other Phase III studies, and whether the other Phase III studies are to continue, Xu tells investors in a research note. She sees the next key catalysts for Incyte shares as the baricitinib advisory panel on April 23, and data from Jakafi Phase II pivotal REACH1 study in steroid-refractory acute graft-versus-host disease in the first half 2018.

TODAY'S FREE FLY STORIES

VIPS

Vipshop

$7.97

-1.015 (-11.30%)

09:47
08/14/18
08/14
09:47
08/14/18
09:47
Hot Stocks
Vipshop falls -11.6% »

Vipshop is down -11.6%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 10

    Sep

HUYA

HUYA

$28.05

-4.81 (-14.64%)

09:47
08/14/18
08/14
09:47
08/14/18
09:47
Hot Stocks
HUYA falls -14.4% »

HUYA is down -14.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWCH

Switch

$10.47

-3.49 (-25.00%)

09:47
08/14/18
08/14
09:47
08/14/18
09:47
Hot Stocks
Switch falls -25.1% »

Switch is down -25.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUMC

Yum China

$36.25

2.03 (5.93%)

09:47
08/14/18
08/14
09:47
08/14/18
09:47
Hot Stocks
Yum China rises 6.1% »

Yum China is up 6.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

AAP

Advance Auto Parts

$153.90

9.11 (6.29%)

09:47
08/14/18
08/14
09:47
08/14/18
09:47
Hot Stocks
Advance Auto Parts rises 6.6% »

Advance Auto Parts is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

TPR

Tapestry

$51.19

3.77 (7.95%)

09:47
08/14/18
08/14
09:47
08/14/18
09:47
Hot Stocks
Tapestry rises 7.8% »

Tapestry is up 7.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 12

    Sep

AAP

Advance Auto Parts

$144.79

(0.00%)

09:44
08/14/18
08/14
09:44
08/14/18
09:44
Technical Analysis
Technical Take: Advance Auto Parts at new 52-week high after earnings »

In early trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

FB

Facebook

$180.08

(0.00%)

, BABA

Alibaba

$177.65

(0.00%)

09:44
08/14/18
08/14
09:44
08/14/18
09:44
Hot Stocks
Jana Partners buys Facebook and Alibaba in Q2, sells out of Northrop »

Barry Rosenstein's…

FB

Facebook

$180.08

(0.00%)

BABA

Alibaba

$177.65

(0.00%)

MSFT

Microsoft

$108.24

(0.00%)

WFC

Wells Fargo

$57.64

(0.00%)

GOOGL

Alphabet Class A

$1,248.76

(0.00%)

GOOG

Alphabet

$1,235.10

(0.00%)

BLMN

Bloomin' Brands

$18.13

(0.00%)

NOC

Northrop Grumman

$292.10

(0.00%)

KDP

Keurig Dr Pepper

$23.75

(0.00%)

WRK

WestRock

$54.73

(0.00%)

CI

Cigna

$181.78

(0.00%)

EA

Electronic Arts

$131.29

(0.00%)

A

Agilent

$65.95

(0.00%)

AAPL

Apple

$208.87

(0.00%)

TIF

Tiffany

$130.88

(0.00%)

LRCX

Lam Research

$178.13

(0.00%)

HDS

HD Supply

$43.72

(0.00%)

ADSK

Autodesk

$133.41

(0.00%)

BSX

Boston Scientific

$33.30

(0.00%)

ZBH

Zimmer Biomet

$122.45

(0.00%)

JACK

Jack in the Box

$89.03

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 15

    Aug

  • 15

    Aug

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 28

    Aug

  • 04

    Sep

  • 10

    Sep

  • 11

    Sep

  • 12

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

  • 18

    Sep

  • 28

    Oct

  • 06

    Nov

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

F

Ford

$9.46

(0.00%)

, BABA

Alibaba

$177.65

(0.00%)

09:42
08/14/18
08/14
09:42
08/14/18
09:42
Hot Stocks
Ford-owned Autonomic announces partnership with Alibaba Cloud »

Autonomic, a wholly owned…

F

Ford

$9.46

(0.00%)

BABA

Alibaba

$177.65

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 23

    Aug

  • 31

    Aug

  • 10

    Sep

CMI

Cummins

$139.70

(0.00%)

, BZUN

Baozun

$52.66

(0.00%)

09:40
08/14/18
08/14
09:40
08/14/18
09:40
Options
Unusually active option classes on open August 14th »

Unusual total active…

CMI

Cummins

$139.70

(0.00%)

BZUN

Baozun

$52.66

(0.00%)

TPR

Tapestry

$47.42

(0.00%)

HD

Home Depot

$194.11

(0.00%)

SWN

Southwestern Energy

$5.34

(0.00%)

NWL

Newell Brands

$20.47

(0.00%)

XLE

Energy Select Sector SPDR

$74.30

(0.00%)

FXI

iShares China Large-Cap ETF

$42.15

(0.00%)

M

Macy's

$40.08

(0.00%)

BABA

Alibaba

$177.65

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 15

    Aug

  • 23

    Aug

  • 10

    Sep

  • 12

    Sep

  • 17

    Sep

09:40
08/14/18
08/14
09:40
08/14/18
09:40
General news
U.S. corporate bond update: issuance remains solid »

U.S. corporate bond…

DB

Deutsche Bank

$11.44

-0.375 (-3.17%)

09:39
08/14/18
08/14
09:39
08/14/18
09:39
Periodicals
Deutsche Bank to review contract of IB head Ritchie in Oct., Financial News says »

Deutsche Bank will review…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNL

Synalloy

$23.55

(0.00%)

09:39
08/14/18
08/14
09:39
08/14/18
09:39
Hot Stocks
Breaking Hot Stocks news story on Synalloy »

Synalloy trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

SWCH

Switch

$13.96

-0.11 (-0.78%)

09:36
08/14/18
08/14
09:36
08/14/18
09:36
Recommendations
Switch analyst commentary  »

Switch price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$194.11

-2.19 (-1.12%)

09:35
08/14/18
08/14
09:35
08/14/18
09:35
Hot Stocks
Breaking Hot Stocks news story on Home Depot »

Home Depot says tariff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

F

Ford

$9.46

-0.275 (-2.82%)

09:33
08/14/18
08/14
09:33
08/14/18
09:33
Periodicals
Ford recalls nearly 4,000 cars in Russia, Reuters reports »

Ford is recalling 3,968…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 31

    Aug

CPT

Camden Property

$92.39

-0.01 (-0.01%)

09:31
08/14/18
08/14
09:31
08/14/18
09:31
Recommendations
Camden Property analyst commentary  »

Camden Property price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

09:30
08/14/18
08/14
09:30
08/14/18
09:30
General news
Stocks open higher as Turkey concerns ease »

Stock futures traded…

ABIL

Ability

$5.95

1.38 (30.20%)

09:30
08/14/18
08/14
09:30
08/14/18
09:30
Syndicate
Ability announces $3.35M registered direct offering »

Ability announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
08/14/18
08/14
09:30
08/14/18
09:30
General news
The U.S. July trade price report was weak »

The U.S. July trade price…

TPR

Tapestry

$47.42

-0.52 (-1.08%)

09:29
08/14/18
08/14
09:29
08/14/18
09:29
Hot Stocks
Tapestry expects 'modest' net decrease in Coach brand stores in FY19 »

Says will continue to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 12

    Sep

DHT

DHT Holdings

$4.31

-0.015 (-0.35%)

09:29
08/14/18
08/14
09:29
08/14/18
09:29
Downgrade
DHT Holdings rating change  »

DHT Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ABIL

Ability

$5.95

1.38 (30.20%)

09:28
08/14/18
08/14
09:28
08/14/18
09:28
Syndicate
Ability announces registered direct offering »

Ability Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGEN

Tecogen

$3.33

0.03 (0.91%)

09:25
08/14/18
08/14
09:25
08/14/18
09:25
Hot Stocks
Tecogen receives U.S. patent for catalyst formulation for Ultera emissions »

Tecogen has been granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

MAR

Marriott

$120.48

0.23 (0.19%)

09:25
08/14/18
08/14
09:25
08/14/18
09:25
Upgrade
Marriott rating change  »

Marriott upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.